Tag: cancer
-
Drug Maker Gains Access to Hidden Protein Immunotherapies
Global drug maker Boehringer Ingelheim is gaining access to an immunotherapy technology that targets usually hidden proteins to attack cancer cells.
-
Drug Price Disruptor Biotech Raises $500M in New Funds
A start-up biotechnology company that aims to bring drugs to market at lower cost is raising $500 million in its second venture funding round.
-
Digital Therapeutics Designed for Cancer/Covid-19 Stress
A digital health company is partnering with cancer advocacy organizations to provide electronic therapies to help patients deal with stresses from Covid-19.
-
Synthetic Biology Company Raises $105M in New Funds
A company developing cellular and genetic therapies for cancer designed like electronic circuits is raising $105 million in its second venture round.
-
Synthetic Virus Company Forms, Raises $77M
A new biotechnology enterprise is underway that develops synthetic viruses attacking solid tumor cancers, based on research at the Salk Institute.
-
Trial Testing Ultrasound, Chemo for Brain Tumors
A clinical trial is underway assessing an implanted ultrasound device with chemotherapy to treat glioblastoma, an aggressive form of brain cancer.
-
Biotech Licenses Precision Cancer Biologic to Genentech
A biotechnology company discovering synthetic proteins that target cancer-causing genetic mutations is licensing its lead product to biologics maker Genentech.
-
Bayer Gains Lung Cancer Therapy in $670M Deal
Global drug maker Bayer AG is licensing an engineered T-cell therapy to treat mesothelioma and other solid tumor cancers from biotech Atara Biotherapeutics.
-
Biotech Creating More Efficient Crispr Therapies
A biotechnology company is developing treatments for cancer and other diseases using Crispr gene editing delivered with more efficient synthetic proteins.
-
Natural-Killer Cell Cancer Therapy Biotech Launches
A new company is underway creating off-the-shelf engineered cells from the immune system as cancer treatments, and raising $42 million in venture funds.